One response to “Sequenom Discloses SEC Inquiry Into Announcement of SEQureDx Down Syndrome Test”

  1. Interesting update. Many of these types of actions lead to a maze of class action lawsuits, from securities actions, to mass tort to derivative actions. Here is a link to pending actions relating to biotech and pharma.

    http://www.classadvocate.com/?direct=y&category=industry&industry_root%5B%5D=16